NASDAQ: CMNDClearmind Medicine Inc Stock
$1.05-0.07 (-6.25%)
Updated Apr 21, 2025
CMND Price
$1.05
Fair Value Price
$1.11
Market Cap
$4.93M
52 Week Low
$0.85
52 Week High
$2.30
P/E
-0.86x
P/B
1.73x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$4.96M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.31
Operating Cash Flow
-$5M
Beta
0.21
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CMND Overview
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CMND's potential to beat the market
- CMND doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CMND
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important CMND news, forecast changes, insider trades & much more!
CMND News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CMND scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CMND ($1.05) is undervalued by 5.15% relative to our estimate of its Fair Value price of $1.11 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CMND ($1.05) is not significantly undervalued (5.15%) relative to our estimate of its Fair Value price of $1.11 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CMND is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CMND due diligence checks available for Premium users.
Valuation
CMND fair value
Fair Value of CMND stock based on Discounted Cash Flow (DCF)
Price
$1.05
Fair Value
$1.11
Undervalued by
5.15%
CMND ($1.05) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CMND ($1.05) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CMND is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CMND price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.86x
Industry
-184.27x
Market
27.14x
CMND price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.73x
Industry
4.04x
CMND is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CMND's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.1M
Profit Margin
0%
CMND's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$6.6M
Liabilities
$3.7M
Debt to equity
1.31
CMND's short-term assets ($6.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CMND's short-term assets ($6.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CMND's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.3M
Investing
$69.5k
Financing
$404.8k
CMND's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CMND vs Biotech Stocks
Clearmind Medicine Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.